What is Sanara MedTech Inc.'s earnings per share (EPS)?

Sanara MedTech Inc. (SMTI) reported diluted earnings per share of -$4.36 for fiscal year 2025. This represents a -282.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sanara MedTech Inc. (SMTI) Financials

SMTI

Trailing 12 months to June 30, 2026

Revenue $109.8M +13.0% YoY

Net Income $43.1M +359.0% YoY

EPS (Diluted) -$3.72 -220.7% YoY

Free Cash Flow $4.5M +5368.1% YoY

Market Cap $320.8M as of Sep 12, 2026

Price / Sales 2.9x on $109.8M revenue, trailing 12 months to June 30, 2026

Price / Earnings 7.4x on $43.1M net income, trailing 12 months to June 30, 2026

Price / Book 40.4x on $7.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SMTI SEC filings page.

Sanara MedTech Inc. (SMTI) reported $109.8M in revenue over the twelve months to Jun 30, 2026, up 13.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SMTI FY2025 2026-08-29

Sanara’s dominant mechanic is rapid revenue scaling with improving operating margins, but debt now amplifies a thin equity base.

From FY2024 to FY2025, operating cash flow moved from near zero to $6.8M while free cash flow reached $2.2M, marking a shift toward cash conversion after reinvestment. Yet FY2025 net income of $37.6M was far above operating income of $7.3M, so reported profitability was influenced by non-operating items rather than operations alone.

Revenue moved from $86.7M in FY2024 to $103.1M in FY2025 while operating costs absorbed less of the incremental sales. Operating margin widened from 1.5% to 7.1%, indicating improved operating leverage rather than growth alone.

Debt-to-equity rose from 0.8x to 7.7x in FY2025, leaving a much thinner equity cushion. Total liabilities were $67.0M against $5.9M of equity, so the reported ROE of 632.5% is mathematically magnified by the small denominator.

Financial Health Signals

Financial Health Score 45/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Sanara MedTech Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Sanara MedTech Inc. has an operating margin of 7.1%, meaning the company retains $7 of operating profit per $100 of revenue. This results in a moderate score of 38/100, indicating healthy but not exceptional operating efficiency. This is up from 1.5% the prior year.

Growth

Sanara MedTech Inc.'s revenue surged 19.0% year-over-year to $103.1M, reflecting rapid business expansion. This strong growth earns a score of 87/100.

Leverage

Sanara MedTech Inc. has elevated debt relative to equity (D/E of 7.74), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 25/100, reflecting increased financial risk.

Liquidity

Sanara MedTech Inc.'s current ratio of 1.80 indicates adequate short-term liquidity, earning a score of 53/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Sanara MedTech Inc.'s free cash flow margin of 2.1% results in a low score of 25/100. Capital expenditures of $4.6M absorb a large share of operating cash flow.

Returns

Sanara MedTech Inc.'s ROE of 632.5% shows moderate profitability relative to equity, earning a score of 42/100. This is up from 24.5% the prior year.

Altman Z-Score Safe

3.42

Sanara MedTech Inc. scores 3.42, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($320.8M) relative to total liabilities ($67.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Sanara MedTech Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.18x

For every $1 of reported earnings, Sanara MedTech Inc. generates $0.18 in operating cash flow ($6.8M OCF vs $37.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

1.08x

Sanara MedTech Inc. earns $1.08 in operating income for every $1 of interest expense ($7.3M vs $6.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$28.1M

YoY+9.0%

QoQ+1.2%

5Y CAGR+35.0%

10Y CAGR+36.4%

Sanara MedTech Inc. generated $28.1M in revenue in Q2 2026. This represents an increase of 9.0% from the same quarter a year earlier. Against the prior quarter it is up 1.2%.

EBITDA

$2.4M

YoY-24.4%

QoQ-25.8%

Sanara MedTech Inc.'s EBITDA was $2.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 24.4% from the same quarter a year earlier. Against the prior quarter it is down 25.8%.

Net Income

-$453K

YoY+77.5%

QoQ-198.7%

Sanara MedTech Inc. reported -$453K in net income in Q2 2026. This represents an increase of 77.5% from the same quarter a year earlier. Against the prior quarter it is down 198.7%.

EPS (Diluted)

-$0.05

YoY+78.3%

QoQ-200.0%

Sanara MedTech Inc. earned -$0.05 per diluted share (EPS) in Q2 2026. This represents an increase of 78.3% from the same quarter a year earlier. Against the prior quarter it is down 200.0%.

Cash & Balance Sheet

Free Cash Flow

$2.0M

YoY+125.2%

QoQ+181.0%

Sanara MedTech Inc. generated $2.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 125.2% from the same quarter a year earlier. Against the prior quarter it is up 181.0%.

Cash & Debt

$15.4M

YoY-9.1%

QoQ+13.4%

5Y CAGR-8.8%

10Y CAGR+52.6%

Sanara MedTech Inc. held $15.4M in cash against $46.5M in long-term debt as of Q2 2026.

Shares Outstanding

YoY+3.2%

QoQ+0.3%

5Y CAGR+3.8%

10Y CAGR-21.9%

Sanara MedTech Inc. had 9M shares outstanding in Q2 2026. This represents an increase of 3.2% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

93.0%

YoY+0.5pp

QoQ-0.1pp

5Y change+1.5pp

10Y change+9.7pp

Sanara MedTech Inc.'s gross margin was 93.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.

Operating Margin

6.3%

YoY-3.3pp

QoQ-3.2pp

5Y change+22.7pp

10Y change+78.2pp

Sanara MedTech Inc.'s operating margin was 6.3% in Q2 2026, reflecting core business profitability. This is down 3.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.2 percentage points.

Net Margin

-1.6%

YoY+6.2pp

QoQ-3.3pp

5Y change+17.6pp

10Y change+71.7pp

Sanara MedTech Inc.'s net profit margin was -1.6% in Q2 2026, showing the share of revenue converted to profit. This is up 6.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.3 percentage points.

Return on Equity

-5.7%

YoY0.0pp

QoQ-12.2pp

5Y change-2.2pp

Sanara MedTech Inc.'s ROE was -5.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. That is unchanged from the same quarter a year earlier. Against the prior quarter it is down 12.2 percentage points.

Capital Allocation

R&D Spending

$1.2M

YoY+9.2%

QoQ+52.0%

5Y CAGR+61.8%

Sanara MedTech Inc. invested $1.2M in research and development in Q2 2026. This represents an increase of 9.2% from the same quarter a year earlier. Against the prior quarter it is up 52.0%.

Capital Expenditures

$5K

YoY-99.7%

QoQ-87.9%

5Y CAGR-24.2%

10Y CAGR+135.6%

Sanara MedTech Inc. invested $5K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 99.7% from the same quarter a year earlier. Against the prior quarter it is down 87.9%.

Share Buybacks

Not reported for Q2 2026.

SMTI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SMTI quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$109.8M	$103.1M+19.0%	$86.7M+33.4%	$65.0M+41.8%	$45.8M+89.9%	$24.1M+54.9%	$15.6M+32.5%	$11.8M+101.6%	$5.8M-7.4%	$6.3M+14.5%	$5.5M+63.3%	$3.4M+28.1%	$2.6M+52.5%	$1.7M+47.1%	$1.2M-46.9%	$2.2M
Cost of Revenue	$7.7M	$7.5M-7.6%	$8.1M+3.7%	$7.9M+23.5%	$6.4M+175.2%	$2.3M+43.0%	$1.6M+33.7%	$1.2M+138.3%	$507K-37.0%	$806K-14.6%	$944K+5.8%	$892K+11.0%	$804K+1.4%	$793K-0.7%	$799K-0.1%	$800K
Gross Profit	$102.2M	$95.6M+21.7%	$78.5M+37.4%	$57.1M+44.7%	$39.5M+80.8%	$21.8M+56.3%	$14.0M+32.3%	$10.6M+98.1%	$5.3M-3.1%	$5.5M+20.5%	$4.6M+84.0%	$2.5M+35.6%	$1.8M+95.9%	$934K+149.0%	$375K-73.4%	$1.4M
R&D Expenses	$5.0M	$5.1M+79.3%	$2.8M-31.5%	$4.1M+22.7%	$3.4M+502.7%	$559K+1290.2%	$40K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$84.4M	$78.7M+9.8%	$71.7M+25.8%	$57.0M+24.0%	$46.0M+63.9%	$28.1M+50.2%	$18.7M+42.9%	$13.1M+127.8%	$5.7M+8.7%	$5.3M+33.7%	$3.9M+16.8%	$3.4M-11.9%	$3.8M+0.6%	$3.8M-33.2%	$5.7M+107.8%	$2.7M
Operating Income	$8.4M	$7.3M+480.3%	$1.3M+129.9%	-$4.2M+66.3%	-$12.5M-69.7%	-$7.4M-46.5%	-$5.0M-83.7%	-$2.7M-446.0%	-$502K-516.7%	$120K+144.3%	-$272K+71.8%	-$965K	N/A	N/A	N/A	-$5.0M
EBITDA	N/A	$11.3M+82.0%	$6.2M+1244.6%	-$540K+94.7%	-$10.1M-49.7%	-$6.8M-42.9%	-$4.7M-81.0%	-$2.6M-526.9%	-$418K-307.9%	$201K+195.2%	-$211K+76.7%	-$905K	N/A	N/A	N/A	-$4.5M
Interest Expense	$7.3M	$6.8M+116.1%	$3.1M+557.5%	$476K+67.1%	$285K+39948.7%	$711-93.8%	$12K-89.1%	$106K+22.3%	$87K-31.7%	$127K-27.3%	$174K-1.4%	$177K-39.8%	$294K-83.0%	$1.7M+502.0%	$287K+209.3%	-$262K
Income Tax	N/A	N/A	$48K	N/A	-$5.8M	N/A	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A
Net Income	$43.1M	$37.6M+288.7%	$9.7M+124.6%	$4.3M+154.2%	-$7.9M-0.2%	-$7.9M-78.2%	-$4.4M-58.0%	-$2.8M-368.6%	-$601K-281.3%	$331K+179.7%	-$416K+69.0%	-$1.3M+41.2%	-$2.3M+45.1%	-$4.1M-124.8%	-$1.8M+85.5%	-$12.7M
EPS (Basic)	N/A	-$4.36-282.5%	-$1.14-119.2%	-$0.52+48.0%	-$1.00+7.4%	-$1.08-42.1%	-$0.76+42.4%	-$1.32	$0.00	$0.00+100.0%	-$0.01	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$3.72	-$4.36-282.5%	-$1.14-119.2%	-$0.52+48.0%	-$1.00	N/A	-$0.76	-$1.32	$0.00	$0.00	-$0.01	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	9M+1.6%	8M+2.5%	8M+4.7%	8M+7.7%	7M+28.0%	6M	2M	217M+4.1%	209M	109M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$28.1M+9.0%	$27.8M+18.6%	$27.5M+4.7%	$26.3M+21.5%	$25.8M+28.0%	$23.4M+26.4%	$26.3M+48.7%	$21.7M+35.2%
Cost of Revenue	$2.0M+2.3%	$1.9M+4.8%	$1.9M-16.7%	$1.9M-5.9%	$1.9M-3.6%	$1.8M-2.9%	$2.2M+25.8%	$2.0M+13.7%
Gross Profit	$26.2M+9.6%	$25.9M+19.8%	$25.7M+6.7%	$24.5M+24.3%	$23.9M+31.5%	$21.6M+29.8%	$24.1M+51.3%	$19.7M+37.9%
R&D Expenses	$1.2M+9.2%	$760K-20.1%	$2.0M+1703.5%	$1.0M+31.4%	$1.1M+7.2%	$950K+0.4%	$113K-82.7%	$784K-20.5%
SG&A Expenses	$22.6M+15.1%	$21.9M+14.4%	$20.1M+5.1%	$19.9M+14.1%	$19.6M+3.6%	$19.1M+18.1%	$19.1M+16.9%	$17.4M+25.5%
Operating Income	$1.8M-28.4%	$2.6M+220.6%	$1.1M-78.5%	$2.9M+277.8%	$2.5M+186.2%	$826K+153.9%	$4.9M+2266.8%	$779K+185.9%
EBITDA	$2.4M-24.4%	$3.2M+65.8%	$2.6M-62.8%	$3.6M+140.8%	$3.2M+278.5%	$1.9M+557.4%	$6.9M+695.6%	$1.5M+1521.0%
Interest Expense	$1.8M+1.0%	$1.8M+36.6%	$1.8M+42.2%	$1.8M+96.0%	$1.8M+178.0%	$1.3M+392.7%	$1.3M	$928K+392.6%
Net Income	-$453K+77.5%	$459K+113.0%	$73.5M+313.2%	-$30.4M-964.2%	-$2.0M+42.5%	-$3.5M-99.9%	$17.8M+112.6%	-$2.9M-169.5%
EPS (Basic)	-$0.05+78.3%	$0.05+112.2%	-$0.180.0%	-$3.52-935.3%	-$0.23+43.9%	-$0.41-95.2%	-$0.18-500.0%	-$0.34-161.5%
EPS (Diluted)	-$0.05+78.3%	$0.05+112.2%	-$0.32-77.8%	-$3.40-900.0%	-$0.23+43.9%	-$0.41-95.2%	-$0.18-500.0%	-$0.34-161.5%
Diluted Shares (Avg)	9M-3.0%	9M+4.9%	N/A	9M+5.0%	9M+5.4%	9M+1.8%	N/A	9M+2.2%

Not reported in any period shown, so not listed: Income Tax.

SMTI Balance Sheet

SMTI quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$72.9M-17.2%	$88.1M+19.3%	$73.9M+21.0%	$61.0M+67.7%	$36.4M+270.4%	$9.8M-11.6%	$11.1M+550.3%	$1.7M-22.9%	$2.2M+2.1%	$2.2M+56.0%	$1.4M-7.1%	$1.5M+53.3%	$977K-29.9%	$1.4M-63.6%	$3.8M
Current Assets	$33.5M+0.7%	$33.3M+75.2%	$19.0M-7.8%	$20.6M-16.2%	$24.6M+449.0%	$4.5M-49.4%	$8.9M+423.8%	$1.7M-17.0%	$2.0M+2.1%	$2.0M+72.3%	$1.2M-4.3%	$1.2M+85.0%	$654K-37.3%	$1.0M-34.3%	$1.6M
Cash & Equivalents	$16.6M+4.4%	$15.9M+208.5%	$5.1M-42.5%	$9.0M-52.0%	$18.7M+3996.2%	$455K-93.1%	$6.6M+3647.8%	$176K-61.9%	$463K-44.4%	$833K+357.1%	$182K-65.2%	$523K+1074.9%	$45K-2.9%	$46K+1171.1%	$4K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.9M+43.4%	$2.8M-41.6%	$4.7M+32.9%	$3.5M+73.3%	$2.0M+78.4%	$1.1M+53.8%	$747K+60.4%	$465K-34.6%	$711K+104.2%	$348K-15.0%	$410K+1.8%	$403K+30.9%	$308K-32.3%	$454K+67.5%	$271K
Accounts Receivable	$12.0M	N/A	N/A	$6.8M+137.9%	$2.9M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$64K
Long-Term Investments	$14.6M+135.4%	$6.2M+101.4%	$3.1M0.0%	$3.1M-38.5%	$5.0M+356.1%	$1.1M	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$67.0M+36.3%	$49.2M+67.9%	$29.3M+51.6%	$19.3M+209.3%	$6.2M+56.7%	$4.0M-15.6%	$4.7M+320.9%	$1.1M-46.9%	$2.1M-18.5%	$2.6M-2.6%	$2.7M+14.6%	$2.3M-32.6%	$3.4M-33.7%	$5.2M-32.4%	$7.7M
Current Liabilities	$18.6M+21.8%	$15.3M+11.1%	$13.8M+7.5%	$12.8M+112.6%	$6.0M+70.1%	$3.5M+34.1%	$2.6M+135.1%	$1.1M-46.9%	$2.1M+51.7%	$1.4M-4.4%	$1.5M-37.0%	$2.3M-32.8%	$3.4M-31.2%	$5.0M-27.2%	$6.9M
Non-Current Liabilities	$48.4M+42.8%	$33.9M+118.4%	$15.5M+138.4%	$6.5M+2830.0%	$222K-50.2%	$446K-78.6%	$2.1M	$0	$0-100.0%	$1.2M-0.3%	$1.2M+13846.2%	$9K	$0-100.0%	$189K-76.6%	$810K
Long-Term Debt	$46.0M+49.8%	$30.7M+236.8%	$9.1M	N/A	N/A	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.9M-84.9%	$39.4M-12.1%	$44.8M+7.2%	$41.8M+36.5%	$30.6M+398.2%	$6.2M-3.8%	$6.4M+989.4%	$587K+472.3%	$103K+124.2%	-$423K+66.7%	-$1.3M-54.0%	-$825K+66.6%	-$2.5M+35.1%	-$3.8M+1.4%	-$3.9M
Retained Earnings	-$75.3M-99.3%	-$37.8M-34.8%	-$28.0M-19.8%	-$23.4M-53.6%	-$15.2M-116.6%	-$7.0M-162.8%	-$2.7M-2035.0%	$138K+100.3%	-$46.9M+0.7%	-$47.2M-0.9%	-$46.8M-2.9%	-$45.4M-5.3%	-$43.2M-10.6%	-$39.0M-5.0%	-$37.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$69.1M-30.0%	$69.3M-28.1%	$72.9M-17.2%	$71.1M-19.7%	$98.8M+34.6%	$96.4M+35.9%	$88.1M+19.3%	$88.5M+19.9%
Current Assets	$32.2M-4.4%	$31.2M-15.3%	$33.5M+0.7%	$31.2M-2.1%	$33.7M+61.8%	$36.8M+114.4%	$33.3M+75.2%	$31.9M+64.7%
Cash & Equivalents	$15.4M-9.1%	$13.6M-34.3%	$16.6M+4.4%	$14.9M-8.2%	$17.0M+175.7%	$20.7M+631.5%	$15.9M+208.5%	$16.3M+161.0%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.5M-1.5%	$3.1M-1.2%	$3.9M+43.4%	$3.4M+12.6%	$3.5M-1.5%	$3.2M-25.3%	$2.8M-41.6%	$3.0M-40.1%
Accounts Receivable	$12.6M	$13.6M	$12.0M	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$13.7M+30.6%	$14.2M+32.5%	$14.6M+135.4%	$12.6M+51.3%	$10.5M+240.9%	$10.7M+246.6%	$6.2M+101.4%	$8.3M+169.8%
Goodwill	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%
Total Liabilities	$61.2M-3.4%	$62.3M+4.3%	$67.0M+36.3%	$64.9M+32.3%	$63.4M+98.2%	$59.7M+114.0%	$49.2M+67.9%	$49.1M+56.5%
Current Liabilities	$12.5M-16.0%	$13.7M+3.2%	$18.6M+21.8%	$17.4M+21.0%	$14.9M+28.6%	$13.3M+4.2%	$15.3M+11.1%	$14.3M+8.4%
Non-Current Liabilities	$48.7M+0.4%	$48.6M+4.6%	$48.4M+42.8%	$47.6M+36.9%	$48.5M+137.6%	$46.4M+206.4%	$33.9M+118.4%	$34.8M+91.5%
Long-Term Debt	$46.5M+5.1%	$46.2M+6.5%	$46.0M+49.8%	$45.1M+49.9%	$44.2M+207.7%	$43.4M+395.0%	$30.7M+236.8%	$30.1M+218.0%
Total Equity	$7.9M-77.6%	$7.0M-80.8%	$5.9M-84.9%	$6.1M-84.5%	$35.4M-15.1%	$36.7M-15.3%	$39.4M-12.1%	$39.8M-10.2%
Retained Earnings	-$74.9M-73.0%	-$74.5M-80.3%	-$75.3M-99.3%	-$73.7M-103.3%	-$43.3M-29.7%	-$41.3M-38.2%	-$37.8M-34.8%	-$36.2M-30.4%

SMTI Cash Flow Statement

SMTI quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$5.7M	$6.8M+28634.4%	-$24K+99.3%	-$3.2M+41.6%	-$5.6M-15.4%	-$4.8M-19.3%	-$4.0M-86.1%	-$2.2M-882.1%	$277K+298.2%	-$140K-134.2%	$409K+134.0%	-$1.2M+28.7%	-$1.7M+7.4%	-$1.8M-48.6%	-$1.2M-256.9%	-$344K
Depreciation & Amortization	N/A	$3.9M-19.8%	$4.9M+34.0%	$3.7M+55.0%	$2.4M+297.2%	$597K+104.9%	$291K+142.9%	$120K+43.0%	$84K+4.0%	$81K+32.5%	$61K+1.4%	$60K+6.4%	$56K+9.3%	$52K-15.5%	$61K-87.0%	$471K
Stock-Based Compensation	N/A	$5.2M+16.2%	$4.4M+28.9%	$3.4M+27.4%	$2.7M+1.3%	$2.7M+90.2%	$1.4M	$0	N/A	N/A	N/A	N/A	N/A	N/A	$531K	$0
Capital Expenditures	$1.2M	$4.6M+2147.1%	$206K-22.4%	$265K+80.4%	$147K-14.5%	$172K-68.4%	$544K+197.8%	$183K+2055.4%	$8K-80.7%	$44K+1349.2%	$3K-43.2%	$5K-33.9%	$8K-73.0%	$30K	N/A	N/A
Free Cash Flow	$4.5M	$2.2M+1041.1%	-$230K+93.5%	-$3.5M+38.4%	-$5.7M-14.3%	-$5.0M-8.9%	-$4.6M-94.8%	-$2.4M-974.8%	$269K+246.2%	-$184K-145.2%	$406K+133.6%	-$1.2M+28.7%	-$1.7M+8.5%	-$1.9M	N/A	N/A
Investing Cash Flow	-$5.9M	-$15.0M-126.5%	-$6.6M+35.2%	-$10.2M-190.7%	-$3.5M+33.6%	-$5.3M-92.6%	-$2.7M-129.3%	-$1.2M-14013.4%	-$8K+90.1%	-$86K-2735.1%	-$3K+43.2%	-$5K+36.9%	-$8K+71.7%	-$30K-108.0%	$372K+127.8%	-$1.3M
Financing Cash Flow	-$1.3M	$8.9M-48.8%	$17.4M+80.1%	$9.6M+1636.8%	-$627K-102.2%	$28.3M+4446.9%	$622K-93.6%	$9.8M	$0+100.0%	-$145K-159.0%	$245K-71.8%	$867K-60.1%	$2.2M+17.5%	$1.9M+106.4%	$897K-45.1%	$1.6M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$1K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$2.0M-23.5%	-$2.5M-23.3%	$3.9M+323.3%	$2.2M+6.1%	$2.7M+288.7%	-$2.0M-25.4%	$932K+209.8%	$2.1M+92.7%
Depreciation & Amortization	$619K-10.1%	$587K-47.8%	$668K-58.4%	$611K-12.3%	$689K-37.7%	$1.1M+1.7%	$1.6M+46.9%	$697K-30.1%
Stock-Based Compensation	N/A	$1.0M-21.2%	N/A	$1.2M+20.2%	$1.4M+1.7%	$1.3M+62.4%	N/A	$1.0M+19.6%
Capital Expenditures	$5K-99.7%	$44K-97.5%	$82K+13.8%	$1.1M+11547.8%	$1.8M+2897.4%	$1.7M+2517.3%	$72K+33.0%	$9K-94.7%
Free Cash Flow	$2.0M+125.2%	-$2.5M+32.6%	$3.9M+349.2%	$1.1M-45.3%	$903K+161.4%	-$3.7M-124.2%	$860K+195.2%	$2.0M+128.4%
Investing Cash Flow	-$5K+99.9%	-$44K+99.2%	-$2.4M-1781.1%	-$3.4M+46.2%	-$3.9M-6584.5%	-$5.2M-7770.0%	-$130K-139.5%	-$6.4M+37.1%
Financing Cash Flow	-$206K+91.6%	-$475K-104.0%	$139K+111.6%	-$775K-105.4%	-$2.5M-151.4%	$12.0M+1919.7%	-$1.2M-546.1%	$14.4M+56.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SMTI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SMTI quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	92.7%+2.1pp	90.6%+2.7pp	87.9%+1.8pp	86.1%-4.3pp	90.4%+0.8pp	89.6%-0.1pp	89.7%-1.6pp	91.3%+4.1pp	87.2%+4.3pp	82.9%+9.3pp	73.6%+4.1pp	69.5%+15.4pp	54.1%+22.1pp	32.0%-31.9pp	63.8%
Operating Margin	7.1%+5.6pp	1.5%+7.9pp	-6.5%+20.8pp	-27.3%+3.2pp	-30.6%+1.8pp	-32.3%-9.0pp	-23.3%-14.7pp	-8.6%-10.5pp	1.9%+6.9pp	-4.9%+23.7pp	-28.6%	N/A	N/A	N/A	-226.9%
Net Margin	36.4%+25.3pp	11.2%+4.5pp	6.6%+23.9pp	-17.3%+15.5pp	-32.8%-4.3pp	-28.5%-4.6pp	-23.9%-13.6pp	-10.3%-15.5pp	5.3%+12.8pp	-7.5%+32.2pp	-39.8%+46.8pp	-86.5%	-240.3%	-157.2%	-576.6%
Return on Equity	632.5%+608.0pp	24.5%+14.9pp	9.6%+28.6pp	-19.0%+6.9pp	-25.9%+46.4pp	-72.3%-28.3pp	-44.0%+58.3pp	-102.4%-425.5pp	323.1%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	51.5%+40.5pp	11.0%+5.1pp	5.8%+18.8pp	-13.0%+8.8pp	-21.8%+23.5pp	-45.2%-19.9pp	-25.3%+9.8pp	-35.1%-50.1pp	14.9%+34.1pp	-19.1%+77.2pp	-96.3%+55.7pp	-152.0%+272.5pp	-424.5%-292.1pp	-132.4%+200.0pp	-332.4%
Current Ratio	1.80-0.4x	2.18+0.8x	1.38-0.2x	1.61-2.5x	4.09+2.8x	1.27-2.1x	3.35+1.8x	1.51+0.5x	0.96-0.5x	1.43+0.6x	0.79+0.3x	0.52+0.3x	0.190.0x	0.210.0x	0.23
Debt-to-Equity	7.74+7.0x	0.78+0.6x	0.20-0.3x	0.46+0.3x	0.20-0.4x	0.65+0.6x	0.00-1.9x	1.91-18.7x	20.63	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	1.41+0.4x	0.98+0.1x	0.88+0.1x	0.75+0.1x	0.66-0.9x	1.59+0.5x	1.06-2.4x	3.42+0.6x	2.84+0.3x	2.54+0.1x	2.42+0.7x	1.760.0x	1.77+0.9x	0.84+0.3x	0.58
FCF Margin	2.1%+2.4pp	-0.3%+5.1pp	-5.4%+7.0pp	-12.4%+8.2pp	-20.6%+8.7pp	-29.4%-9.4pp	-20.0%-24.6pp	4.6%+7.5pp	-2.9%-10.3pp	7.4%+43.2pp	-35.8%+28.5pp	-64.4%	-107.3%	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	93.0%+0.5pp	93.1%+0.9pp	93.2%+1.7pp	92.9%+2.1pp	92.5%+2.5pp	92.2%+2.4pp	91.5%+1.6pp	90.8%+1.7pp
Operating Margin	6.3%-3.3pp	9.5%+6.0pp	3.8%-14.8pp	11.2%+7.6pp	9.6%+23.9pp	3.5%+11.8pp	18.6%+19.9pp	3.6%+9.3pp
Net Margin	-1.6%+6.2pp	1.7%+16.7pp	266.9%	-115.5%	-7.8%+9.6pp	-15.0%-5.5pp	67.6%+20.3pp	-13.2%-6.6pp
Return on Equity	-5.7%0.0pp	6.5%+16.1pp	1238.0%+1192.8pp	-494.6%-487.4pp	-5.7%+2.7pp	-9.6%-5.5pp	45.1%+26.5pp	-7.2%-4.8pp
Return on Assets	-0.7%+1.4pp	0.7%+4.3pp	100.8%+80.6pp	-42.8%-39.6pp	-2.0%+2.7pp	-3.7%-1.2pp	20.2%+8.9pp	-3.2%-1.8pp
Current Ratio	2.58+0.3x	2.28-0.5x	1.80-0.4x	1.80-0.4x	2.26+0.5x	2.77+1.4x	2.18+0.8x	2.23+0.8x
Debt-to-Equity	5.85+4.6x	6.58+5.4x	7.74+7.0x	7.33+6.6x	1.25+0.9x	1.18+1.0x	0.78+0.6x	0.76+0.5x
Asset Turnover	0.41+0.1x	0.40+0.2x	0.38+0.1x	0.37+0.1x	0.260.0x	0.240.0x	0.30+0.1x	0.240.0x
FCF Margin	7.2%+3.7pp	-9.0%+6.8pp	14.0%+10.7pp	4.2%-5.2pp	3.5%+10.8pp	-15.9%-6.9pp	3.3%+8.4pp	9.4%+3.8pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Sanara MedTech Inc. SMTI	FY2025	$103.1M	$37.6M	36.4%	$320.8M	45/100
AngioDynamics, Inc. ANGO	FY2026	$320.2M	-$36.7M	-11.5%	$631.1M	36/100
Embecta Corp. EMBC	FY2025	$1.1B	$95.4M	8.8%	$279.9M	56/100
Kestra Medical Technologies, Ltd. KMTS	FY2026	$95.1M	-$131.6M	N/A	$1.3B	50/100
Stereotaxis, Inc. STXS	FY2025	$32.4M	-$21.6M	-66.8%	$129.3M	42/100
OraSure Technologies Inc OSUR	FY2025	$115.0M	-$68.7M	-59.8%	$224.1M	48/100

Where Sanara MedTech Inc. Ranks

Frequently Asked Questions

What is Sanara MedTech Inc.'s annual revenue?

Sanara MedTech Inc. (SMTI) reported $103.1M in total revenue for fiscal year 2025. This represents a 19.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Sanara MedTech Inc.'s revenue growing?

Sanara MedTech Inc. (SMTI) revenue grew by 19.0% year-over-year, from $86.7M to $103.1M in fiscal year 2025.

Is Sanara MedTech Inc. profitable?

Yes, Sanara MedTech Inc. (SMTI) reported a net income of $37.6M in fiscal year 2025, with a net profit margin of 36.4%.

What is Sanara MedTech Inc.'s EBITDA?

Sanara MedTech Inc. (SMTI) had EBITDA of $11.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Sanara MedTech Inc. have?

As of fiscal year 2025, Sanara MedTech Inc. (SMTI) had $16.6M in cash and equivalents against $46.0M in long-term debt.

What is Sanara MedTech Inc.'s gross margin?

Sanara MedTech Inc. (SMTI) had a gross margin of 92.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Sanara MedTech Inc.'s operating margin?

Sanara MedTech Inc. (SMTI) had an operating margin of 7.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Sanara MedTech Inc.'s net profit margin?

Sanara MedTech Inc. (SMTI) had a net profit margin of 36.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Sanara MedTech Inc.'s return on equity (ROE)?

Sanara MedTech Inc. (SMTI) has a return on equity of 632.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Sanara MedTech Inc.'s free cash flow?

Sanara MedTech Inc. (SMTI) generated $2.2M in free cash flow during fiscal year 2025. This represents a 1041.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Sanara MedTech Inc.'s operating cash flow?

Sanara MedTech Inc. (SMTI) generated $6.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Sanara MedTech Inc.'s total assets?

Sanara MedTech Inc. (SMTI) had $72.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Sanara MedTech Inc.'s capital expenditures?

Sanara MedTech Inc. (SMTI) invested $4.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Sanara MedTech Inc. spend on research and development?

Sanara MedTech Inc. (SMTI) invested $5.1M in research and development during fiscal year 2025.

How many shares does Sanara MedTech Inc. have outstanding?

Sanara MedTech Inc. (SMTI) had 9M shares outstanding as of fiscal year 2025.

What is Sanara MedTech Inc.'s current ratio?

Sanara MedTech Inc. (SMTI) had a current ratio of 1.80 as of fiscal year 2025, which is generally considered healthy.

What is Sanara MedTech Inc.'s debt-to-equity ratio?

Sanara MedTech Inc. (SMTI) had a debt-to-equity ratio of 7.74 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sanara MedTech Inc.'s return on assets (ROA)?

Sanara MedTech Inc. (SMTI) had a return on assets of 51.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Sanara MedTech Inc.'s P/E ratio?

Sanara MedTech Inc. (SMTI) trades at 7.4x earnings, its market capitalization divided by net income of $43.1M net income, trailing 12 months to June 30, 2026. The market capitalization is $320.8M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Sanara MedTech Inc.'s price-to-sales ratio?

Sanara MedTech Inc. (SMTI) trades at 2.9x sales, its market capitalization divided by revenue of $109.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $320.8M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Sanara MedTech Inc.'s Altman Z-Score?

Sanara MedTech Inc. (SMTI) has an Altman Z-Score of 3.42, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Sanara MedTech Inc.'s Piotroski F-Score?

Sanara MedTech Inc. (SMTI) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sanara MedTech Inc.'s earnings high quality?

Sanara MedTech Inc. (SMTI) has an earnings quality ratio of 0.18x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Sanara MedTech Inc. cover its interest payments?

Sanara MedTech Inc. (SMTI) has an interest coverage ratio of 1.08x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Sanara MedTech Inc.?

Sanara MedTech Inc. (SMTI) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.